PT 141 dosage female guide: bremelanotide is approved at 1.75 mg under the skin, at least 45 minutes before sex, once per day, eight times a month.
The FDA-approved PT-141 dosage for females is 1.75 mg injected subcutaneously, at least 45 minutes before anticipated sexual activity, with no more than one dose in any 24-hour period. PT-141 is the research name for bremelanotide, sold as the brand Vyleesi, and it is approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). There is no FDA-approved PT-141 dose for men, and the drug is not a hormone, a testosterone booster, or an erectile dysfunction treatment.
What PT-141 (Bremelanotide) Is
Bremelanotide is a synthetic melanocortin receptor agonist that works on signaling in the central nervous system rather than on blood flow. It is a modified form of alpha-melanocyte-stimulating hormone, which explains why repeated use can darken the skin.
The FDA approved Vyleesi in June 2019 for premenopausal women with HSDD, a condition defined by persistently low sexual desire that causes personal distress. The approval does not extend to men, to postmenopausal women, or to people who simply want a short-term boost in libido.
PT-141 is not a PDE5 inhibitor like sildenafil or tadalafil. Those drugs change blood flow, while bremelanotide changes brain pathways tied to desire, which is why the dosing history for women and men looks so different.
The Approved PT-141 Dose and How to Use It
The approved pt-141 dosage for women is a fixed 1.75 mg subcutaneous injection with no titration phase. Women do not start low and build up, and there is no higher dose for someone who feels the first injection did not work.
Timing, Limits, and Injection Basics
- Inject at least 45 minutes before anticipated sexual activity.
- Rotate sites between the abdomen and the front of the thigh.
- Limit use to one dose in 24 hours.
- Limit use to eight doses in a 30-day period.
- Do not inject into skin that is bruised, tender, scarred, or tattooed.
The 45-minute mark is a minimum, not a precise countdown. Some women notice effects earlier and some later, and the medication is generally described as active for several hours.
Why the Dose Is Capped at 1.75 mg
Higher bremelanotide doses were tested in clinical trials, and they produced more nausea and vomiting without a clear increase in benefit. The 1.75 mg dose was selected to balance tolerability against effectiveness. Taking a second injection to improve a disappointing result increases side effects and falls outside the label.
PT-141 Dosing Table: Women, Men, and Research Use
Comparing pt-141 dosage male figures with female figures is a common source of confusion, because the numbers are not interchangeable. Many popular versions of a pt-141 peptide dosage chart blend FDA-labeled dosing with doses that appeared only in early trials.
| Group | Commonly cited dose | Route and timing | FDA status |
|---|---|---|---|
| Premenopausal women with HSDD | 1.75 mg | Subcutaneous, at least 45 minutes before activity; max 1 per 24 hours, 8 per month | Approved (Vyleesi) |
| Men (clinical trial research) | 10 mg | Subcutaneous single dose in trials | Not approved |
| Postmenopausal women | Not established | — | Not approved |
| Recreational or bodybuilding use | No standard; user reports vary widely | Subcutaneous, self-directed | Not approved; products unregulated |
A frequent claim is that men should take roughly six times the female dose, but that comparison is misleading. The 10 mg figure comes from trials in men with erectile dysfunction, not from an approved product, and the FDA has never cleared bremelanotide for male use.
Postmenopausal women are another group with no established dose, because the pivotal trials enrolled premenopausal participants. Extending the 1.75 mg dose to older women is an assumption rather than an evidence-based recommendation.
PT-141 Dosage in mL: What the Syringe Number Means
Questions about pt-141 dosage in ml only make sense once you know the concentration of the product in front of you. The approved autoinjector delivers 1.75 mg in 0.3 mL, so the volume is fixed and there is nothing to calculate.
Research-grade vials are sold as dry powder measured in milligrams, and the buyer adds a diluent such as bacteriostatic water. The resulting concentration, usually written as mg per mL, determines what volume corresponds to a given milligram dose.
A 10 mg vial reconstituted with 2 mL of water yields 5 mg/mL, so 1.75 mg would equal 0.35 mL. That arithmetic looks simple on paper but is easy to get wrong when the vial label, the diluent volume, and the syringe scale are reported in different units.
Two safety points matter here. Unapproved peptides sold online are not verified for identity, purity, or sterility, so the label may not match the contents. A concentration error can also turn into a large unintended dose.
Side Effects and Who Should Avoid PT-141
Nausea is the most commonly reported side effect and can be severe enough that some women stop treatment. Flushing, headache, vomiting, injection site reactions, and short-term changes in blood pressure are also reported.
Repeated use has been linked to focal hyperpigmentation, meaning dark patches on the skin, gums, or lips. The risk appears to increase with more frequent dosing, and monitoring guidance recommends periodic checks for new pigmentation.
Bremelanotide can temporarily raise blood pressure and lower heart rate, so it is not appropriate for people with uncontrolled hypertension or significant cardiovascular disease. It is contraindicated during pregnancy and breastfeeding, and alcohol may worsen nausea.
Anyone considering PT-141 should review their medical history and current medications with a healthcare professional. This article is educational and does not replace personalized medical advice.
The Bottom Line on PT-141 Dosing
The approved pt-141 female dosage is 1.75 mg subcutaneously, at least 45 minutes before sex, capped at one dose per day and eight doses per month. That number is fixed by the label and does not scale with body weight, age, or response.
PT-141 is not a cure for low sexual desire, and it does not work for everyone. In the clinical trials behind approval, average improvements in desire and distress were modest, and the medication is meant to be used alongside broader care.
Doses circulating for men, for bodybuilding, and for compounded vials come from research studies or personal reports rather than regulatory review. If PT-141 is prescribed to you, follow the label exactly and report side effects to your clinician.
Frequently Asked Questions
How much PT-141 should a woman take?
The FDA-approved dose for premenopausal women with HSDD is 1.75 mg injected subcutaneously, at least 45 minutes before anticipated sexual activity. It should not be used more than once in 24 hours or more than eight times in a month. There is no approved higher dose, and increasing the dose raises the risk of nausea and vomiting.
Can women use the 10 mg PT-141 dose that is sold for men?
No. The 10 mg dose comes from clinical trials in men and is not part of any FDA-approved product. Higher bremelanotide doses caused more nausea and vomiting in studies without clearly better results. The FDA has not approved bremelanotide for men at any dose.
How long before sex should you inject PT-141?
The label directs users to inject at least 45 minutes before anticipated sexual activity, and the effect is generally described as lasting several hours. Response varies from person to person. If a dose does not produce the desired effect, do not inject again the same day.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.